To assess maturation of hPSC-CMs, biochemical, structural, and biophysical parameters are commonly used in the field including measurements of gene expression, cell shape and size, sarcomeric lengths and organizations, conduction velocity, mitochondria-to-cell volume ratio, resting membrane potential, calcium transient kinetics and cellular ATP levels, and force of contractions. 10, 11, [16] [17] [18] [19] [20] Many promising
H uman pluripotent stem cell-derived cardiomyocytes (hP-SC-CMs) have been widely used for cardiac disease modeling, [1] [2] [3] drug discovery, 4, 5 and cardiac toxicity screenings [6] [7] [8] in vitro. Unlike primary human cardiomyocytes which have limited availability and are difficult to maintain in culture, hP-SC-CMs can be easily generated and cultured in vitro with unlimited quantities. They have also been shown to exhibit similar electrical activities and contractile capabilities compared with primary cardiomyocytes. 9, 10 However, hPSC-CMs exhibit metabolically and functionally immature phenotypes when cultured in traditional culture media. [11] [12] [13] They mainly use glycolysis for energy production in vitro as opposed to the predominantly oxidative metabolism observed in normal adult hearts.
approaches have been proposed to enhance hPSC-CMs' maturation including biophysical, biochemical, and bioelectrical stimulations. 10 Ribeiro et al, 21 for example, showed improved cardiomyocyte-shortening velocities, action potential amplitudes, improved sarcomeric organizations, and lower resting membrane potentials by culturing hPSC-CMs in commercial media optimized for cardiomyocyte maturation. By combining 3-dimensional, aligned cardiac tissues with electrical stimulations, Nunes et al 18 demonstrated improvements in cardiomyocyte ultrastructural organization and conduction velocities. Recently, Kadota et al 22 showed an improved maturation of hPSC-CMs transplanted in rat hearts. While most studies focused on characterizing cardiomyocytes' morphological, electrical, and contractile phenotypes, the role of energy substrate and metabolic pathway utilization on cardiomyocyte maturation remains relatively less well studied. Several signaling molecules have been identified as important factors in promoting maturation of hPSC-CMs including AMPK (5' AMP-activated protein kinase)/ mTORC1 (mammalian target of rapamycin complex 1) pathway, 23 thyroid hormone, 24, 25 and microRNAs. 20, 26 In a recent publication, Correia et al 15 showed that by depriving glucose and supplementing fatty acids in the culture media, hPSC-CMs are metabolically and functionally more mature. However, the regulatory pathways that controls hPSC-CMs' metabolic maturation remain to be elucidated.
During heart development, a major metabolic switch from glycolytic to oxidative energy production occurs shortly after birth. 27 In the fetal heart, most of ATP is produced by glycolytic breakdown of glucose, whereas the majority of ATP synthesis in the adult heart comes from fatty acid β-oxidation in the mitochondria. 27 Since tremendous amount of energy is required constantly for proper heart function, it is essential for mature cardiomyocytes to use oxidative phosphorylation as a robust and effective pathway for ATP synthesis. Therefore, the metabolic switch to oxidative energy production is a hallmark of cardiac metabolic maturation.
HIF1α (hypoxia-inducible factor 1α) has been identified as a primary transcriptional factor and master regulator of cellular hypoxia responses in multiple organ systems in the body. 28, 29 Under physiological conditions, HIF1α is targeted by E3 ubiquitin ligase von Hippel-Lindau tumor suppressor and degraded rapidly by the ubiquitin protease pathway. A decrease in cellular oxygen levels stabilizes HIF1α and causes HIF1α proteins to accumulate in the nucleus. 30, 31 An extensive body of literature has shown that HIF1α acts as a central regulator of metabolism in a variety of cell types and promotes glycolytic pathways and suppresses oxidative energy production in the mitochondria. 32 The adaptive activation of HIF1α in hypoxic tumor promotes cancer cell survivor and growth by activating a large number of downstream transcripts regulating cellular metabolism and proliferation. [32] [33] [34] [35] Okamoto et al 36 have recently shown that HIF1α reduces cellular oxygen consumption and mitochondria electron transport chain activities. 
Novelty and Significance
What Is Known?
• Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are a ready source for in vitro human cardiac disease modeling, drug discovery, and toxicity screening.
• Cultured hPSC-CMs maintain an immature metabolic phenotype in which the majority of ATP is produced through aerobic glycolysis instead of oxidative phosphorylation.
• Glucose deprivation results in a metabolic shift from glycolysis to oxidative phosphorylation and improves functional maturation of hPSC-CM; however, the pathways that regulate metabolic maturation of these cells remain poorly understood.
What New Information Does This Article Contribute?
• CMs cultured in the presence of glucose aberrantly upregulate hypoxia-inducible factor 1α (HIF1α) and its downstream target-lactate dehydrogenase A, 2 factors that are known to promote aerobic glycolysis.
• Glucose deprivation results in the inhibition of HIF1α and lactate dehydrogenase A activity, and repression of aerobic glycolysis.
• Small molecule or siRNA inhibition of HIF1α or small molecule inhibition of LDHA (lactate dehydrogenase A) results in a metabolic switch from aerobic glycolysis to oxidative phosphorylation, a more mature metabolic phenotype.
• The metabolic maturation promoted by HIF1α inhibition improves functional maturation of hPSC-CMs.
hPSC-CMs have found widespread use in cardiac disease modeling, drug discovery, and toxicity screenings in vitro. Mature adult myocardial cells rely on fatty acid oxidation for energy production. In contrast, hPSC-CMs cultured in vitro maintain an immature metabolic phenotype, where a majority of ATP is produced through aerobic glycolysis, not oxidative phosphorylation. Herein, we show that hPSC-CMs cultured in the presence of glucose aberrantly upregulate HIF1α and its downstream target LDHA. Whereas, glucose deprivation promotes oxidative phosphorylation and represses HIF1α activity. Small molecule inhibition of HIF1α or LDHA triggers a switch from aerobic glycolysis to oxidative phosphorylation as does siRNA inhibition of HIF1α. This metabolic maturation is accompanied by an increase in mitochondrial content, increased cellular ATP levels, improved functional gene expression, increased sarcomere length, and improved contractility. These findings provide key insights into the regulation of metabolic and functional maturation of hPSC-CMs and may be used to generate more physiologically mature cardiomyocytes for drug screening, disease modeling, and therapeutic applications. October 12, 2018
HIF1α activation has also been shown to upregulate glycolytic enzymes including lactate dehydrogenase A (LDHA), which is required for the conversion of pyruvate to lactate. 37, 38 Because LDHA plays a critical role in cancer metabolism, targeting LDHA has been proposed as a potential therapeutic strategy for inhibiting tumorigenesis 39, 40 and several small molecule inhibitors of LDHA activity have been generated and validated.
In the heart, HIF1α signaling has been shown to control metabolic signaling during cardiac development and maturation in vivo. [41] [42] [43] HIF1α signaling has also been shown to be required for cardiomyocyte proliferation during the mid-gestation stage. Furthermore, cardiac-specific HIF1α deletion results in severe alterations in cardiac calcium flux, contractility, and energy availability. Early ablation of HIF1α has been shown to produce severe cardiac defects and embryonic lethality. 44 Recently, Menendez-Montes et al 43 showed that HIF1α signaling is essential in controlling the in vivo embryonic metabolic switch from glycolysis to oxidative phosphorylation, which is essential for cardiac maturation in vivo. Given the central role of HIF1α in regulating metabolic substrate selection and the abnormal glucose utilization in hPSC-CMs, we hypothesized that the HIF1α-LDHA signaling pathway plays an essential role in regulating metabolic and functional maturation of cultured cardiomyocytes.
Accordingly, the aim of this study is to investigate the underlying signaling mechanism controlling cardiomyocytes' energy substrate selection and metabolic maturation of hPSC-CMs. To address this, we investigated the metabolic and physiological consequences of culturing hPSC-CMs in 3 different media compositions: glucose media (GLM), GLM supplemented with fatty acids (GFAM), and fatty acids only media (FAM) deprived of glucose. Metabolic and functional characterizations of cardiomyocytes cultured in these 3 media reveal that glucose-rich medium promotes glycolytic metabolism, even in the presence of fatty acids, whereas media containing fatty acids as the only energy source allowed for normal physiological metabolic substrate utilization. We then show that HIF1α-LDHA axis is aberrantly upregulated in cardiomyocytes cultured on glucose-containing media. Small molecule inhibition of the HIF1α-LDHA pathway results in enhanced metabolic and functional maturation of hPSC-CMs. Collectively, our results highlight the importance of controlling the metabolic maturation of stem cell-derived cardiomyocytes to generate viable stem cell models of human cardiovascular disease in vitro.
Methods
The authors declare that all supporting data are available within the article (and its Online Data Supplement).
Human Pluripotent Stem Cell Culture and Differentiation
The pluripotent stem cells used in this study include HUES9 (NIH Human Embryonic Stem Cell Registry Number 0022; generated by HSCI iPS Core at Harvard University), H7 (WA07; NIH Human Embryonic Stem Cell Registry Number 0067; generated by WiCell Research Institute), and iPSC (induced pluripotent stem cell; BJ RiPS-D-Healthy Donor Control [Male], generated by HSCI iPS Core at Harvard University). We characterized the pluripotency of these stem cells and found no significant difference between several pluripotency markers (Online Figure I) .
The schematic of Figure 1A illustrates the hPSC culture, differentiation, and dissociation timeline. hPSC-CM differentiation methods were adapted from previously published manuscripts. 6, 10, 15, 45, 46 The 3 media compositions used are as follows: GLM contains Roswell Park Memorial Institute medium (RPMI) medium with GlutaMAX Supplement (Thermo Fisher Scientific, MA) plus Gem21 NeuroPlex Serum-Free Supplement (Gemini Bio-Products, CA). GFAM contains GLM plus 50 µmol/L of palmitic acid (Sigma, MO) and 100 µmol/L oleic acid. FAM contains RPMI medium with GlutaMAX Supplement without glucose (Thermo Fisher Scientific, MA) plus 50 µmol/L of palmitic acid (Sigma, MO) and 100 µmol/L oleic acid. 15, 47 To prepare the fatty acids, stock solutions of palmitic acid and oleic acid were made by dissolving fatty acid powder in dimethyl sulfoxide at 37ºC followed by vortex mixing and aseptic filtration. The stock solutions were prepared fresh for each new media. Cardiomyocytes were cultured in different media compositions with or without small molecule treatments for 7 days before experiments. Media was refreshed at day 4 after replacing with the appropriate substrates and small molecules.
Animal Procedures and Hexokinase Activity Assay
C57BL/6 mouse was used in this study. Hearts from embryonic day 15, postnatal day 2, and adult mice were harvested in lysis buffer and homogenized using TissueLyser LT (Qiagen, Germany). Mice studies were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital. Hexokinase activity assays were performed using a commercial assay kit (BioVision, CA) according to manufacture-suggested protocol. Hexokinase converts glucose into glucose-6-phosphate, which is oxidized to form NADH (nicotinamide adenine dinucleotide). The resulting NADH then reduces a colorless probe into a colorimetric product indicative of the hexokinase enzyme activity levels.
Adult cardiomyocytes were isolated using direct enzyme injection protocol. 48 Briefly, C57BL/6 mice were anesthetized and cut open below the diaphragm to expose the heart. After injection of 7 mL EDTA buffer to the right ventricle, the aorta was clamped by forceps and the heart was removed. Multiple rounds of injections to the apex of the heart were performed with the following: 10 mL EDTA buffer, 3 mL of perfusion buffer, and 30 mL of collagenase buffer. The hearts were then pulled apart using forceps and filtered through 100 μm strainers to remove large tissue debris. After 3 rounds of gravity settling, the adult cardiomyocytes were resuspended in culture media.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (La Jolla, CA). The sample size for each group is shown in the figure legends. Results for single cell assays were collected from at least 3 sets of independent experiments. Experimental sample sizes, normality test results, statistical testing, and post hoc corrections used are detailed in Online Table II . Statistical significance was defined as P<0.05.
Results

hPSC-CMs Cultured in GLM and GFAM Lacks Metabolic and Functional Maturation
Prior reports have suggested that the mammalian embryonic heart depends on glycolysis for ATP production, whereas the adult heart switches to primarily oxidative phosphorylation to produce energy. To verify these findings and establish a baseline control for hPSC-CMs, we followed the changes in glycolysis rates of at different stages of heart development and maturation. We measured hexokinase enzyme activity levels of heart samples from embryonic day 15, postnatal day 2, and adult mice using colorimetric commercial assay kit. As expected, we observed significantly higher hexokinase activities in immature embryonic and postnatal hearts compared with Figure 1 . Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) cultured in glucose media lack metabolic and functional maturity. A, Schematic representation of experimental timeline including stem cell culture, cardiomyocyte differentiation, purification, culture, and treatments. Different media used at different days of the timeline indicated. B, Relative hexokinase enzyme activity in heart tissue samples from embryonic (n=7 embryos), neonatal (n=10 mice), and adult mice (n=9 mice). C, Relative hexokinase enzyme activity in hPSC-CMs cultured in glucose media (GLM), glucose and fatty acid media (GFAM), and FAM (n=1 iPSC [induced pluripotent stem cell] line and 2 ESC [embryonic stem cell] lines). D, Lactate measurements of hPSC-CMs cultured in GLM, GFAM, and FAM (n=1 iPSC line and 2 ESC lines). E, Baseline oxygen consumption rate (OCR) measurements of hPSC-CMs cultured in GLM, GFAM, and FAM normalized to cell number (n=1 iPSC line and 2 ESC lines). F, Mitochondria respiration rates of hPSC-CMs cultured in GLM, GFAM, and FAM per 30 000 cells (n=1 iPSC line and 2 ESC lines). G, ATP measurements of hPSC-CMs cultured in GLM, GFAM, and FAM (n=1 iPSC line and 2 ESC lines). H, Histogram of hPSC-CMs cultured in GLM, GFAM, and FAM with mitotracker staining analyzed by FACS with a representative mitotracker staining; 10 000 events recorded per group. I, Mean mitotracker staining intensities of hPSC-CMs cultured in GLM, GFAM, and FAM (n=1 iPSC line and 2 ESC lines). J, Sarcomere lengths measurements of hPSC-CMs cultured in GLM, GFAM and FAM (n=1 iPSC line and 2 ESC lines) with a representative α-actinin staining, green and orange lines represent hPSC-CMs' and adult cardiomyocytes' sarcomere lengths reported in the literature, respectively. 10, 19, 22 K, Contractile force generated by single hPSC-CMs cultured in GLM, GFAM, and FAM (n=1 iPSC line and 2 ESC lines). October 12, 2018 adult hearts ( Figure 1B) . We then used the same hexokinase assay to compare the glycolysis rates of hPSC-CMs cultured in glucose-containing media (GLM; GFAM) and media with fatty acids as the only energy source (FAM). hPSC-CMs cultured in FAM had significantly lower hexokinase activities compared with cardiomyocytes cultured in GLM and GFAM ( Figure 1C) . No difference in hexokinase protein levels was observed among the 3 groups (Online Figure V) . Glycolysis results in the conversion of glucose into pyruvate, which is subsequently reduced into lactate. To further validate that the increase in hexokinase activity is because of an increase in glycolysis, we compared the total cellular lactate levels in cardiomyocytes cultured under different growth conditions using a commercial lactate assay kit. As shown in Figure 1D , cardiomyocytes cultured in GLM and GFAM had significantly higher lactate levels compared with cardiomyocytes cultured in FAM. These results show that hPSC-CMs cultured in the glucose-containing media GLM and GFAM have a high glycolytic rate that is similar to embryonic and postnatal hearts. In contrast, cardiomyocytes cultured in FAM media where fatty acids are the only energy source had increased oxidative phosphorylation rates and reduced glycolysis rates as would be expected during myocardial maturation.
We then assessed rates of oxidative metabolism in hPSCCMs cultured in GLM, GFAM, and FAM using the Seahorse Live-cell Metabolic Assay. Cardiomyocytes cultured in GLM and GFAM had significantly lower oxygen consumption rates ( Figure 1E ) compared with cardiomyocytes cultured in FAM. We then performed mitochondria stress test by sequentially adding oligomycin, FCCP (mesoxalonitrile 4-trifluoromethoxyphenylhydrazone), and antimycin to cardiomyocytes cultured in all 3 media. Cardiomyocytes cultured in FAM had a significant increase in oxygen consumption rate with FCCP treatment compared with cardiomyocytes cultured in GLM and GFAM ( Figure 1F ). This response indicates a much larger spare capacity for cardiomyocytes cultured in FAM compared with GLM and GFAM. To assess ATP production, we measured cardiomyocyte ATP levels using the CellTiter-Glo assay. cardiomyocytes cultured in GLM and GFAM had significantly lower levels of ATP per cell compared with cardiomyocytes cultured in FAM ( Figure 1G ). These results support our findings that hPSC-CMs cultured in GLM and GFAM are metabolically reliant on glycolysis rather than oxidative phosphorylation and furthermore that they generate less ATP compared with cardiomyocytes cultured in FAM.
Because oxidative phosphorylation is a mitochondrial process, we then compared the number of mitochondria among hPSC-CMs cultured in GLM, GFAM, and FAM using mitotracker deep red staining and quantitative flow cytometry. We observed that cardiomyocytes cultured in GLM and GFAM have significantly lower median mitotracker intensities compared with that of FAM ( Figure 1H and 1I) . We also observed a higher sarcomere length ( Figure 1J ) and peak contractile force generation ( Figure 1K ) in cardiomyocytes cultured in FAM compared with cardiomyocytes cultured in GLM and GFAM. These results taken together show that cardiomyocytes cultured in the presence of glucose resemble immature embryonic and neonatal cardiomyocytes with respect to their energy substrate utilization, active metabolic pathways, and mitochondrial content. In contrast, cardiomyocytes cultured in the presence of fatty acids as the primary energy source more closely resemble adult cardiomyocytes, consistent with previous reports.
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Aberrant Activation of HIF1α and LDHA Pathway in Cultured Cardiomyocytes
HIF1α is a central regulator of metabolism and promotes glycolysis at the expense of oxidative phosphorylation. 29, 37, 38, 41, 43 To test a potential role for this pathway in controlling the observed inappropriate energy substrate selection in glucosecultured cardiomyocytes, we performed immunofluorescent staining of HIF1α in hPSC-CMs cultured in GLM, GFAM, and FAM. We found that cardiomyocytes cultured in the presence of glucose had high levels of HIF1α in the nucleus and low levels in the cytoplasm (Figure 2A ). This high nuclearto-cytoplasmic ratio of HIF1α protein (Online Figure IVA) and localizations are consistent with the activation of the HIF1α pathway. In contrast, HIF1α was primarily localized to the cytoplasm in cells cultured in FAM ( Figure 2B ). We then quantified HIF1α protein expressions using Western blot. HIF1α was expressed at significantly higher levels in hPSC-CMs cultured in GLM and GFAM compared with FAM ( Figure 2C ). We then measured the mRNA levels of direct and indirect downstream targets of activated HIF1α. Among these transcripts, we found that LDHA has a significantly higher expression in hPSC-CMs cultured in the presence of glucose (GLM and GFAM) compared with those cultured in FAM without glucose ( Figure 2D ). Other transcripts involved in cellular metabolism were not significantly different among the 3 groups (Online Figure IVB and IVC) . Activated HIF1α is a transcriptional regulator that has been previously shown to act in a positive feedback loop to promote its own transcriptional activation. 45, 49, 50 We therefore reasoned that repression of HIF1α activity might result in a normalization of its levels at the mRNA and protein level. To test this, we then evaluated the effect of HIF1α inhibition by treatment with CTM (chetomin), a small molecule inhibitor of HIF1α's transcriptional activity ( Figure 2C ). Inhibition of HIF1α activity normalized its protein expression level. Furthermore, inhibition of HIF1α with CTM also significantly reduced LDHA mRNA levels in GLM-and GFAM-cultured cardiomyocytes ( Figure 2D ). These results demonstrate an aberrant activation of HIF1α in hPSC-CMs cultured in glucose-rich media and raise the possibility that repression of this pathway may result in improved metabolic function of cardiomyocytes cultured in vitro.
Inhibition of HIF1α and LDHA Improves Cardiomyocytes' Metabolic Maturation
To assess the metabolic impact of inhibiting the HIF1α-LDHA regulatory axis, we treated hPSC-CMs cultured in GLM, GFAM, and FAM with GSKA (GSK 2837808A; a selective and potent LDHA inhibitor) or CTM. We first compared hexokinase enzyme activity levels of cardiomyocytes treated with GSKA, CTM, or carrier control and showed that both GSKA and CTM treatments significantly reduced hexokinase enzyme activity levels in cardiomyocytes cultured in GLM and GFAM ( Figure 3A) . Similarly, total cellular lactate levels were also decreased with this treatment ( Figure 3B ). We then compared the cellular ATP levels of cardiomyocytes treated with GSKA or CTM. As shown in Figure 3C and Online Figure VIA , hESC-CM and hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) inhibition of this pathway resulted in an increase of cellular ATP production in cells cultured in GLM and GFAM consistent with the shift from aerobic glycolysis to oxidative phosphorylation. Next, we quantified the impact of GSKA, CTM, or GSKA+CTM treatment on cellular respiration and oxidative metabolism using the Seahorse Analyzer and found that cardiomyocytes treated with GSKA had significantly increased oxygen consumption rates ( Figure 3D ) and spare capacities ( Figure 3E ). These results demonstrate that inhibition of the HIF1α or LDHA inhibits aerobic glycolysis and restores normal cardiomyocyte dependence on oxidative phosphorylation. Metabolic pathway utilizations of cardiomyocytes cultured in FAM, GLM, and GFAM treated with GSKA or CTM are illustrated in scheme 1 in Online Data Supplement. Collectively, these results demonstrate that small molecular inhibition of HIF1α-LDHA promotes cardiomyocytes' metabolic maturation with reduced glycolysis, increased oxidative metabolism, and higher cellular ATP productions. . C, mRNA levels of LDHA and LDHB in hPSC-CMs cultured in GLM, GFAM, and FAM (n=3 independent experiments using HUES9-ESC-CMs). D, mRNA levels of LDHA in hPSC-CMs cultured in GLM, GFAM, and FAM treated with CTM (n=3 independent experiments using HUES9-ESC-CMs). October 12, 2018
Inhibition of HIF1α and LDHA Enhances Cardiomyocytes' Structural and Functional Maturation
To assess the impact of HIF1α-LDHA inhibition on cardiomyocytes' structural maturation, we quantified the sarcomere lengths of cardiomyocytes cultured in GLM, GFAM, and FAM treated with GSKA, CTM, or control. Cardiomyocytes cultured with fatty acids as the only energy source (FAM) had significantly longer sarcomere length compared with cells cultured in the presence of glucose ( Figure 4A ). Likewise, significant improvements in sarcomere lengths were observed in cardiomyocytes treated with GSKA or CTM ( Figure 4A ). We then investigated the impact of metabolic substrate availability and HIF1α-LDHA regulation on mitochondrial content. As shown in Figure 4B , we found a significant increase in mitochondria DNA-to-genomic DNA ratio with CTM or GSKA treatments in cardiomyocytes cultured in GFAM. We also found a similar increase in median mitotracker staining intensities with CTM or GSKA treatments in cardiomyocytes cultured in GFAM ( Figure 4C and 4D) . Likewise, transmission electron microscopy imaging quantification showed several mitochondria per cell normalized to cytoplasmic area. We observed a significant increase in mitochondria number in cardiomyocytes cultured in GFAM with CTM compared with control ( Figure 4E and Online Figure IX) . No significant changes in myofibril content were observed in these experiments. We subsequently examined the effect of HIF1α-LDHA inhibition by treatment with GSKA or CTM on structural and 2 cytoplasmic area for each cell measured by transmission electron microscopy in hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) cultured in control GFAM or GFAM+CTM, (n=20 cells for control GFAM and n=27 GFAM+CTM analyzed, Mann-Whitney U test were used for statistical analysis). F, mRNA levels of selected transcripts involved in CM function and maturation in hiPSC-CMs cultured in GFAM, GFAM treated with GSKA or CTM, and FAM (n=3 independent experiments). All statistical analysis was performed comparing to GFAM controls. October 12, 2018 functional gene expressions. We analyzed several key cardiac functional genes and observed a significant increase in the expression levels of gap junction protein-α1 (GJA1), myosin heavy chain 6 (MYH6), β-myosin heavy chain (MYH7), potassium/sodium hyperpolarization-activated cyclic nucleotidegated channel 4 (HCN4), and sodium voltage-gated channel α-subunit 5 (SCN5A) when cardiomyocytes were treated with GSKA or CTM ( Figure 4F ).
We then quantified the impact of HIF1α-LDHA inhibition on cardiomyocytes' calcium transient kinetics and contractility. We show significant increases in peak calcium amplitude ( Figure 5A and 5B), maximum upstroke and decay velocities ( Figure 5C and 5D) , and decreases in time to 50% upstroke and decay ( Figure 5E and 5F) in cardiomyocytes cultured in GFAM and treated with GSKA or CTM compared with FAM. We also observed significant increases in peak contractile force generations ( Figure 5G) , maximum shortening velocities ( Figure 5H) , and maximum relengthening velocities ( Figure 5I ) in cardiomyocytes cultured in GFAM and treated with GSKA or CTM compared with FAM. Measurements of peak contractile forces of HUES9-CMs (Online Figure VIB) and H7-CMs (Online Figure VIC ) also showed significant increases in GSKA or CTM-treated cardiomyocytes cultured in GLM and GFAM. Subsequently, we performed whole-cell current-patch clamp recordings of cardiac action potentials in hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) cultured in GFAM plus CTM and control. We found that CTMtreated cardiomyocytes showed a significantly more negative resting membrane potential (−75±1 mV; N=6 cells) compared with control group (−70±1 mV; N=6 cells; Figure 5J and 5K) consistent with the finding HIF1α-LDHA inhibition promotes cardiomyocytes' structural and functional maturation.
To confirm that our findings were generalizable, we replicated key experiments with different pluripotent stem cell lines. We used H7-ESC-CMs for cellular metabolic and functional studies. We observed similar improvements in cellular hexokinase activities, ATP per cell, sarcomere lengths, cell size, and median mitotracker intensities with HIF1α-LDHA inhibition (Online Figures VII and XA) . We also assessed the long-term effect of HIF1α-LDHA inhibition in hiPSC-CMs. Similar improvements in mitochondria DNA-to-genomic DNA ratio, median mitotracker intensity, sarcomere lengths, and ATP per cell were observed with 30-day inhibition of HIF1α-LDHA in GFAM-cultured cardiomyocytes (Online Figure VIII) . We also used siRNA inhibition of HIF1α as an alternative approach to promote hPSC-CMs' metabolic and functional maturation (Figure 6 ). In hiPSC-CMs cultured in GFAM treated with HIF1α siRNA, we found similar decrease in hexokinase activities, increases in mitochondria DNA-togenomic DNA ratio, improvements in cellular ATP levels and percentage fractional shortenings from controls compared with CTM small molecular approach ( Figure 6 ).
Discussion
hPSC-CMs have been proposed as a promising cell source for drug development, human disease modeling, and cardiac toxicity screening in vitro. 1, 2, 8 Compared with human adult cardiomyocytes, hPSC-CMs are relatively immature both morphologically and functionally, lacking normal levels of binucleation, well-developed sarcomeres, fast electrical conductivity, and oxidative metabolism. 10 To address these limitations, numerous studies have aimed to enhance hPSC-CMs' maturation using genetic, chemical, and biomechanical approaches. [16] [17] [18] These studies have achieved varying degrees of success in terms of improving hPSC-CMs' morphological, electrical, and contractile maturation. In this study, we focus on cellular metabolism as a critical rubric for maturation state of cardiomyocytes. We have previously shown that culturing hPSC-CMs in fatty acids media in the absence of glucoseenhanced cardiomyocyte maturation. An important caveat of this approach, however, is the cytotoxicity that resulted from the accumulation of lipid intermediates and leading to cellular dysfunction and death. 15 This lipotoxicity occurred only after 10 days of in vitro culture and could be abrogated by the addition of galactose to the culture media. 15 Of important note, however, both glucose and fatty acids are available as potential energy sources for cardiomyocytes in vivo. We therefore sought to investigate the mechanism underlying metabolic substrate selection of hPSC-CMs cultured in the presence of both glucose and fatty acids and to determine how these metabolic pathways controlled myocardial maturation. In doing so, we cultured cardiomyocytes in FAM for 7 days as positive controls, a time point when meaningful cellular maturation could be observed but before the development of lipotoxicity. Accordingly, our study advances the mechanistic understanding of metabolic substrate utilization and at the same time establishes a novel methodology of cardiomyocyte metabolic maturation that is compatible with physiological growth conditions.
Several studies have demonstrated that the embryonic and neonatal mammalian heart depends on aerobic glycolysis as the principal energy production pathway. 27 As a result of a postnatal metabolic shift in cardiomyocyte substrate utilization, the majority of the energy required for cardiomyocytes' contractile function in the adult heart is produced through β-oxidation of fatty acids in the mitochondria. 27 Hexokinase is a key enzyme in glycolysis that converts glucose into glucose-6-phosphate and its activity levels have been used as a surrogate for glycolysis rates. [51] [52] [53] Similarly, lactate, a byproduct of glycolysis in mammalian cells, can be used as an indicator for the level of glycolysis. 27 Transitioning hPSC-CMs from glucose-containing to glucose-free conditions forces an analogous shift in substrate utilization because of the lack of availability of the substrate of glycolysis. 15 In the native heart, although both glucose and fatty acids are available as energy sources, adult cardiomyocytes uses primarily fatty acids for energy production. In contrast, hPSC-CMs cultured in the presence of both glucose and fatty acids preferentially used glucose as the principle energy source. HIF1α has been identified as a master transcriptional regulator of cellular metabolism 28, 38 and its expression is crucial for early fetal cardiac development. 54, 55 Recent studies have further suggested that activation of the HIF1α pathway is required for the maintenance of a myocardial proliferative state during early embryonic development. 43 We, therefore, hypothesized that aberrant activation of this pathway may contribute to the persistence of an immature metabolic phenotype in hPSC-CMs. Activated HIF1α is localized to the nucleus, whereas inactive HIF1α remains in the cytoplasm where it is rapidly turned over. 28, 30, 31 Of note, we show that HIF1α is aberrantly activated in hPSC-CMs cultured in the presence of glucose and inactivated when cells were grown with fatty acids as the only carbon source. Inhibition of HIF1α activity further resulted in a decrease in HIF1α nuclear localization, consistent with prior reports showing that a positive feedback loop coordinates HIF1α activity with its protein localization and transcriptional expression. 45, 49, 50 LDHA is a key target of HIF1α. Its expression is required for the conversion of pyruvate to lactate and the restoration of the cellular NAD + storage required for glycolysis. We show that LDHA is significantly upregulated in hPSC-CMs cultured in the presence of glucose, consistent with the dependence of these cells on glycolytic pathways for energy production. Inhibition of HIF1α activity with CTM resulted in reduced LDHA gene expression, confirming that LDHA is a downstream target of HIF1α in hPSCCMs. Likewise, small molecule inhibition of LDHA activity suppresses aerobic glycolysis and facilitates oxidative phosphorylation in hPSC-CMs. The expression and activity of HIF1α in hPSC-CMs cultured in the presence of glucose is similar to its reported expression during early fetal development. Moreover, deletion of von Hippel-Lindau tumor suppressor during midgestation stage of cardiac development has been shown to stabilize HIF1α proteins and prevent metabolic shift from glycolytic to oxidative pathway resulting in impaired cardiac maturation and function. 43 Aerobic glycolysis has been previously shown to be activated in oncogenesis 32, 34, 40 and inhibiting HIF1α-LDHA signaling in cancer cells decreases glycolysis and lactate fermentation rates, whereas reactivating oxidative phosphorylation. 39, 40 Here, we propose to improve cultured hPSC-CMs' metabolic and functional maturation by shifting its metabolism using small molecule HIF1α-LDHA inhibitors. Indeed, increases in oxygen consumption rate, mitochondria spare capacities, and ATP productions, as well as decreases in cellular hexokinase activity and lactate levels were observed in hPSC-CMs cultured in GLM and GFAM with inhibition of HIF1α/LDHA by CTM/GSKA. Critically, shifting cardiomyocyte metabolism to oxidative pathways promotes cellular maturation including sarcomere lengths, mitochondrial number, functional gene expressions, calcium transient kinetics, and contractile force generation. Furthermore, peak contractile force generated by single hPSC-CMs treated with CTM/GSKA reached similar levels of adult murine cardiomyocytes reported in the literature. 56, 57 These results indicate that inhibiting HIF1α-LDHA signaling is an effective strategy for improving hPSC-CMs' metabolic and functional maturation. We did observe an increase in the expression of HCN4, which has been previously shown to inversely correlate with cardiomyocyte maturation. Jaconi et al showed that HCN4 is highly expressed in ESC (embryonic stem cell) and day 30 ESC-derived cardiomyocytes but dramatically reduces at day 60 of in vitro culture. 58 Interestingly, HCN4 expression is restored by day 110 of culture and at that point is no statistically difference with its expression level for day 30. Because the role of HCN4 during cardiomyocyte maturation in vivo and in vitro is complex and difficult to infer electrical maturation state of cardiomyocytes, we performed whole-cell currentpatch clamp experiments. We observed significantly more negative MDP (maximum diastolic potential) in CTM-treated cardiomyocytes, which supports our conclusions that inhibiting HIF1α promotes hPSC-CMs' electrical maturation.
The findings of this study highlight the importance of bioenergetics and energy substrate utilization in the functional maturation of hPSC-CMs. Aberrant activation of the HIF1α/ LDHA signaling pathway leads to a metabolic shift toward aerobic glycolysis resulting in decreased number of mitochondria, lower cellular ATP levels, impaired calcium handling, and diminished contractility. Correcting hPSC-CMs' metabolic pathway selection and ensuring proper mitochondria function resulted in an increased number of mitochondria, higher cellular ATP levels, improved calcium handling, and contractility. Therefore, this approach may be important in developing more clinically relevant in vitro cardiac disease model and drug-screening platforms using hPSC-CMs.
